Company Update & Newsletter
Welcome to your Q3 recap: R&D milestones, product updates, customer stories, culture highlights, and what’s next for Global Inc., the genetics company accelerating personalized medicine.
A stronger foundation, faster delivery
“Q3 was about building the rails for precision care at scale. We cut time-to-insight by 28%, launched GenomeCloud 2.0, and deepened partnerships with three leading research hospitals.” — Alex Rivera, CEO
CRISPR therapy hits preclinical efficacy
Our GI-142 edit achieved targeted knockdown in 92% of test samples, with no off-target edits detected in the validated panel. This advances our timeline for a Phase I submission by six months.
- New off-target detection pipeline with duplex sequencing
- Automated QC dropped analysis time from 8h → 52m
- Ethics review complete; trial site selection underway
GenomeCloud 2.0 is live
Our analysis platform now delivers cohort-level insights, auto-annotates variants with real-time literature updates, and exports to partner EMRs.
- 20x faster variant annotation
- New privacy-preserving cohort queries
- API for lab LIMS + EMR integration
Welcoming 38 new Globallers
From wet-lab scientists to privacy engineers, we’re growing thoughtfully. Q3 also launched our mentorship program and DEI speaker series.
- 38 new hires across 6 countries
- Mentorship program: 124 active pairs
- Volunteering: 420 hours logged
What’s next
- Clinical validation for GI-142 at two new sites
- GenomeCloud 2.1: automated report drafting
- Partner data hub for hospital consortia
Q3 Town Hall — Oct 1 @ 10:00
Join leadership for Q&A, demos, and a deeper dive on GI-142 and GenomeCloud 2.0.